At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ORIC Oric Pharmaceuticals Inc.
Pre-Market Trading 01-24 08:24:17 EST
10.34
+0.47
+4.76%
High10.60
Low9.69
Vol643.18K
Open9.69
D1 Closing9.87
Amplitude9.27%
Mkt Cap729.66M
Tradable Cap438.99M
Total Shares70.57M
T/O6.60M
T/O Rate1.51%
Tradable Shares42.46M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Oric Pharmaceuticals Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Oric Pharmaceuticals Announces Clinical Supply Agreement to Evaluate Oric-114 in Combination With Amivantamab for the First-Line Treatment of Nsclc With Egfr Exon 20 Insertion Mutations
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.